Keliod treatment.
Conditions
Interventions
Intervention 1: Intervention group: Platelet-Rich Fibrin : For this procedure, approximately 10-20 mL of venous blood is drawn from the patient and centrifuged in special tubes without anticoagulant a
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients aged over 18 years Patients with a confirmed diagnosis of burn-induced keloid(s), with a minimum of 3 lesions Undergoing treatment with IPL laser, CO2 laser, or a combination of both. Having a total affected area of at least 10 × 10 cm² or a lesion with a minimum length of 10 cm. Not pregnant or lactating. Free from underlying medical conditions that could impair scar healing, such as diabetes mellitus or immunosuppression. Patient compliance with all therapeutic interventions and attendance at every treatment session.
Exclusion criteria
Exclusion criteria: Occurrence of pregnancy during the treatment or follow-up period. Development of hypersensitivity or any adverse reaction to any of the treatment interventions that would preclude continuation of therapy Diagnosis of malignancy or a systemic disease during the treatment or follow-up period. Onset of bacterial or viral skin infections during the treatment or follow-up period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vascularity. Timepoint: At baseline (before intervention) and at 1, 2, and 3 months after the initiation of treatment. Method of measurement: Vancouver scar scale.;Pigmentation. Timepoint: At baseline (before intervention) and at 1, 2, and 3 months after the initiation of treatment. Method of measurement: Vancouver scar scale.;Height/Elevation of the Lesion. Timepoint: At baseline (before intervention) and at 1, 2, and 3 months after the initiation of treatment. Method of measurement: Vancouver scar scale.;Pliability of the lesion. Timepoint: At baseline (before intervention) and at 1, 2, and 3 months after the initiation of treatment. Method of measurement: Vancouver scar scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse Events. Timepoint: At 1, 2, and 3 months after the initiation of treatment. Method of measurement: Checklist.;Treatment tolerability. Timepoint: At 1, 2, and 3 months after the initiation of treatment. Method of measurement: Checklist.;Treatment satisfaction. Timepoint: At 1, 2, and 3 months after the initiation of treatment. Method of measurement: Checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammadreza Ghassemi
Iran University of Medical Sciences
Outcome results
None listed